Table 1. Antimicrobial susceptibility profiles, clinical sites and phenotypic of seven Nocardia isolates from humans, Brazil.
| Antimicrobial profilesa | Phenotypic profilesb | ||||||||||||||||||
| Isolate | Clinical site | AMK | GEN | TOB | ERY | CIP | AMP | AMX | IMP | TMP+SMX | 45° | URE | PYR | GEL | RAM | SOR | CAS | NIT | Phenotypic Identification |
| 1046BRRJ * | BALc | Sd | S | Re | S | R | #f | # | S | S | − | + | + | − | + | + | + | − | N. nova |
| 1047BRRJ * | Nodule secretion | S | S | R | S | R | # | # | S | S | + | + | − | − | + | + | − | − | N. asteroides |
| 1048BRRJ * | Tracheal aspirate | S | S | R | S | R | # | # | S | S | + | + | − | − | + | + | − | − | N. asteroides |
| 1261BRRJ | Pulmonary fragment | S | S | S | R | R | # | # | S | S | + | − | − | − | − | + | − | + | N. cyriacigeorgica |
| 1694BRRJ | Cerebral abscess | S | S | S | R | R | S | # | S | S | − | + | + | − | + | − | + | + | Nocardia sp. |
| 2042BRRJ | BAL | S | S | S | S | S | R | R | S | S | + | − | − | − | − | + | − | + | Nocardia sp. |
| 78408BRRJ | # | S | S | S | R | R | # | # | S | S | − | + | − | + | + | + | + | + | N. pseudobrasiliensis |
a
AMK, amikacin; AMX, amoxicillin; AMP, ampicillin; CIP, ciprofloxacin; ERY, erythromycin; GEN, gentamicin; IMP, imipenem; TOB, tobramycin; TMP+SMX, trimethoprim+sulfamethoxazole.
b
45°C, growth at 45°C; URE, urease production; PYR, pyrolidonyl arylamidase production; GEL, hydrolysis of gelatin; RAM, acid production on rhamnose; SOR, acid production on sorbitol; CAS, hydrolysis of casein and NIT, nitrate reduction.
c
BAL - bronchoalveolar lavage fluid;
d
S – sensitive;
e
R – resistant;
f
# Unknown;
*
Clinical isolates obtained from only one patient.